VativoRx, LLC

11/17/2025

Provider trust in PBMs is at its lowest point in 15 years, and hospitals are increasingly seeking more direct visibility into their specialty drug spend.

Edition 17 of The Rebate Report breaks down the latest PSG findings and why more organizations are turning toward independent oversight of rebate-eligible medical-benefit drugs.

https://www.linkedin.com/posts/vativorx-llc_therebatereport-vativorx-hospitalfinance-activity-7396261620747870208-fBUu?utm_source=social_share_send&utm_medium=member_desktop_web&rcm=ACoAAAFXBloBZBzOrhB_kt8c9ooq-NgFFQbJ4ls

11/17/2025

🧠 The FDA has approved Ferabright™, the first iron-based MRI contrast agent for brain imaging. Unlike traditional gadolinium agents, it’s processed naturally by the body — safer for patients with kidney issues.

https://vativorx.com/pharmacy-bulletin-11-17-2025/

On Oct. 17, 2025, the US Food and Drug Administration (FDA) approved Azurity Pharmaceuticals’ Ferabright™ (ferumoxytol injection), the first iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain. Ferabright is indicated for use in adults with known or suspected br...

11/14/2025

👧🧒 The FDA has expanded Simponi®’s approval to treat children (15kg+) with moderate to severe ulcerative colitis. Kids can now receive the same TNF-α–targeting therapy adults use, given every 4 weeks.

https://vativorx.com/pharmacy-bulletin-11-14-2025/

On Oct. 7, 2025, the US Food and Drug Administration (FDA) approved Johnson & Johnson Innovative Medicine’s Simponi® (golimumab) for the treatment of moderate to severe active ulcerative colitis (UC) in pediatric patients who weigh at least 15kg.

11/11/2025

💊 The FDA has approved Celltrion’s Eydenzelt®, a biosimilar to Eylea®, for treating several eye diseases, including wet AMD & diabetic macular edema. It’s the sixth Eylea biosimilar approved, though launch timing remains unknown.

https://vativorx.com/pharmacy-bulletin-11-11-2025/

On Oct. 2, 2025, the US Food and Drug Administration (FDA) approved Celltrion’s Eydenzelt® (aflibercept-boav), a biosimilar to Eylea® (aflibercept – Regeneron) injection, 2mg. Eydenzelt is indicated to treat neovascular (wet) age-related macular degeneration (wAMD), macular edema following ret...

11/06/2025

👧👦 The FDA has approved Tremfya® for kids 6+ with psoriasis (PsO) & psoriatic arthritis (PsA), the first IL-23 inhibitor for children. This expands treatment options for thousands of young patients.

https://vativorx.com/pharmacy-bulletin-11-06-2025/

On Sept. 29, 2025, the US Food and Drug Administration (FDA) approved two new indications for Tremfya® (guselkumab - Johnson & Johnson Innovation Medicine) to treat moderate-to-severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA) in pediatric patients aged six years and older, weighin...

11/04/2025

💉 The FDA approves Merck’s Keytruda® Qlex™, a subcutaneous version of Keytruda for 38 solid tumor types. It offers the same effectiveness as IV Keytruda but can be given in just 1–2 minutes instead of 30. Launched end of September.

https://vativorx.com/pharmacy-bulletin-11-04-2025/

On Sept. 19, 2025, the US Food and Drug Administration (FDA) approved Merck’s Keytruda® Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous (SC) use for the treatment of solid tumors in adults and pediatric patients aged 12 years and older, covering 38 cancer indica...

11/03/2025

👏 The FDA expands Vyjuvek® access for all ages, including newborns, and now allows at-home use for DEB patients. Caregivers can apply this topical gene therapy weekly, making treatment more flexible & accessible.

https://vativorx.com/pharmacy-bulletin-11-03-2025/

On Sept. 15, 2025, the US Food and Drug Administration (FDA) approved label updates for Vyjuvek® (beremagene geperpavec-svdt), Krystal Biotech’s redoseable, topical gene therapy for dystrophic epidermolysis bullosa (DEB).

10/28/2025

💊 Pfizer will retire low-dose Vyndaqel® (tafamidis 20mg) by year-end 2025 to simplify treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Higher-dose Vyndamax® (61mg) offers the same benefit in one daily capsule.

https://vativorx.com/pharmacy-bulletin-10-28-2025/

On Aug. 29, 2025, Pfizer announced plans to discontinue Vyndaqel® (tafamidis meglumine 20mg), by the end of 2025.

10/24/2025

Puerto Rico’s hospitals are caught between capped funding, MA-driven reimbursement limits, and workforce strain—yet care demand keeps climbing.

Edition 16 of The Rebate Report breaks down the island’s financial pressures and how strategic rebate management helps build stability when rates can’t rise.

📖 Read now → https://www.linkedin.com/feed/update/urn:li:activity:7387552215953010688

10/10/2025

Two days until SIIA! Meet our team in Phoenix, Oct 12–14, to explore how rebate recovery offsets rising drug costs.

10/09/2025

🚨 FDA withdraws approval of Ixchiq™ (chikungunya vaccine) after reports of serious adverse events, including 3 deaths & 21 hospitalizations linked to vaccine-related illness. Distribution in the U.S. must stop immediately.

https://vativorx.com/pharmacy-bulletin-10-09-2025/

On Aug. 25, 2025, the US Food and Drug Administration (FDA) suspended approval of Ixchiq™ (live attenuated chikungunya virus vaccine - Valneva SE) for adults at an increased risk of exposure to the chikungunya virus, a mosquito-borne disease that can cause debilitating joint pain, fever and rash.

10/08/2025

Reimbursement volatility is reshaping hospital and outpatient economics. But forward-thinking infusion centers are finding strength where others see loss, by turning compliant rebate capture into a financial safety net.

In this edition of The Rebate Report, we explore how even a small percentage of verified, Part B claims can deliver a six-figure impact, and why that precision matters more than volume.

How is your organization planning for reimbursement stability in 2025?

Read Edition 15: https://www.linkedin.com/pulse/reimbursement-headwinds-rise-revenue-resilience-vativorx-llc-5jtce

Please share your perspective below; we may feature your insight in the next issue.

Hospitals, infusion centers, and outpatient facilities are feeling the squeeze. Payment caps, shifting site-of-care policies, and biosimilar pricing fluctuations have made consistent reimbursement harder to maintain in 2025.